Aytu Biopharma (AYTU) Common Equity (2011 - 2026)
Aytu Biopharma (AYTU) posted quarterly Common Equity of $35.1 million for Q1 2026, up 0.7% year-over-year from $34.9 million in Q1 2025, and up 147.47% quarter-over-quarter from $14.2 million in Q4 2025.
Aytu Biopharma (AYTU) Common Equity (2011 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has reported Common Equity for 16 consecutive years, with $35.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 0.7% year-over-year to $35.1 million; the TTM figure through Mar 2026 stood at $35.1 million (up 0.7% YoY), while the FY2025 annual figure was $19.0 million, down 31.57% from the prior year.
- Common Equity grew to $35.1 million in Q1 2026 per AYTU's latest filing, from $14.2 million in the prior quarter.
- Across five years, Common Equity topped out at $61.1 million in Q1 2022 and bottomed at $14.2 million in Q4 2025.
- Historically, Common Equity has averaged $34.7 million across 5 years, with a median of $32.9 million in 2023.
- On a YoY basis, Common Equity climbed as much as 95.07% in 2022 and fell as far as 67.79% in 2022.
- Aytu Biopharma's Common Equity stood at $45.8 million in 2022, then retreated by 28.3% to $32.9 million in 2023, then retreated by 6.36% to $30.8 million in 2024, then plunged by 53.84% to $14.2 million in 2025, then surged by 147.47% to $35.1 million in 2026.
- Business Quant data shows AYTU's Common Equity at $35.1 million in Q1 2026, $14.2 million in Q4 2025, and $23.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 4.05 Bn |
| 10 | Aytu Biopharma | 24.60 Mn | -2.12 Mn | 7.60 Mn | 35.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.14 Mn |
| Dec 31, 2025 | 14.20 Mn |
| Sep 30, 2025 | 23.17 Mn |
| Jun 30, 2025 | 18.97 Mn |
| Mar 31, 2025 | 34.90 Mn |
| Dec 31, 2024 | 30.77 Mn |
| Sep 30, 2024 | 29.83 Mn |
| Jun 30, 2024 | 27.72 Mn |
| Mar 31, 2024 | 30.78 Mn |
| Dec 31, 2023 | 32.85 Mn |
| Sep 30, 2023 | 32.17 Mn |
| Jun 30, 2023 | 39.36 Mn |
| Mar 31, 2023 | 40.91 Mn |
| Dec 31, 2022 | 45.82 Mn |
| Sep 30, 2022 | 48.35 Mn |
| Jun 30, 2022 | 44.31 Mn |
| Mar 31, 2022 | 61.14 Mn |
| Dec 31, 2021 | 105.54 Mn |
| Sep 30, 2021 | 111.50 Mn |
| Jun 30, 2021 | 137.57 Mn |